| Name | Title | Contact Details |
|---|
Aqualung Therapeutics (ALT) is developing multi-pronged strategies to address the development of severe lung inflammation which is essential to the severity and outcomes of acute and chronic lung disorders such as acute lung injury, ventilator-induced lung injury (VILI), idiopathic pulmonary fibrosis, and pulmonary hypertension.
Pinteon Therapeutics is advancing clinical studies of a novel antibody that aims to interrupt the spread of toxic tau and protect and preserve brain function in patients with neurodegenerative disease.
ADMEDES SCHUESSLER GmbH is a West Chester, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Leading the translation of RNA-modifying protein (RMP) biology into promising new therapies for cancer.
The approach is an autologous, cell-based treatment that activates the full array of patient-specific antigens, resulting in both an innate and adaptive immune response. The company`s lead program is in glioblastoma multiforme (GBM), an extremely aggressive form of brain cancer with a significant unmet need. In parallel, the company is also progressing the platform in a select number of additional solid tumors where the unmet need remains great and where initial immunotherapy approaches have often failed to provide a significant benefit.